NasdaqGS:PCRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. More Details


Snowflake Analysis

Solid track record with moderate growth potential.


Similar Companies

Share Price & News

How has Pacira BioSciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PCRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: PCRX's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

5.0%

PCRX

2.2%

US Pharmaceuticals

-1.0%

US Market


1 Year Return

68.1%

PCRX

3.5%

US Pharmaceuticals

19.6%

US Market

Return vs Industry: PCRX exceeded the US Pharmaceuticals industry which returned 3.7% over the past year.

Return vs Market: PCRX exceeded the US Market which returned 19.6% over the past year.


Shareholder returns

PCRXIndustryMarket
7 Day5.0%2.2%-1.0%
30 Day22.3%4.5%2.2%
90 Day31.6%8.7%11.5%
1 Year68.1%68.1%7.0%3.5%22.3%19.6%
3 Year90.1%90.1%22.8%13.3%45.3%35.7%
5 Year11.6%11.6%52.5%34.4%124.8%99.8%

Long-Term Price Volatility Vs. Market

How volatile is Pacira BioSciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pacira BioSciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PCRX ($73.68) is trading below our estimate of fair value ($148.45)

Significantly Below Fair Value: PCRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PCRX is poor value based on its PE Ratio (24.7x) compared to the US Pharmaceuticals industry average (24.1x).

PE vs Market: PCRX is poor value based on its PE Ratio (24.7x) compared to the US market (21x).


Price to Earnings Growth Ratio

PEG Ratio: PCRX is poor value based on its PEG Ratio (3.2x)


Price to Book Ratio

PB vs Industry: PCRX is overvalued based on its PB Ratio (5.5x) compared to the US Pharmaceuticals industry average (4.4x).


Next Steps

Future Growth

How is Pacira BioSciences forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

7.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCRX's forecast earnings growth (7.7% per year) is above the savings rate (2%).

Earnings vs Market: PCRX's earnings (7.7% per year) are forecast to grow slower than the US market (21.6% per year).

High Growth Earnings: PCRX's earnings are forecast to grow, but not significantly.

Revenue vs Market: PCRX's revenue (12% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: PCRX's revenue (12% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PCRX's Return on Equity is forecast to be high in 3 years time (24.2%)


Next Steps

Past Performance

How has Pacira BioSciences performed over the past 5 years?

43.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PCRX has a high level of non-cash earnings.

Growing Profit Margin: PCRX's current net profit margins (30%) are higher than last year (0.5%).


Past Earnings Growth Analysis

Earnings Trend: PCRX has become profitable over the past 5 years, growing earnings by 43.5% per year.

Accelerating Growth: PCRX's earnings growth over the past year (6162.7%) exceeds its 5-year average (43.5% per year).

Earnings vs Industry: PCRX earnings growth over the past year (6162.7%) exceeded the Pharmaceuticals industry 16.8%.


Return on Equity

High ROE: PCRX's Return on Equity (21.6%) is considered high.


Next Steps

Financial Health

How is Pacira BioSciences's financial position?


Financial Position Analysis

Short Term Liabilities: PCRX's short term assets ($658.5M) exceed its short term liabilities ($86.3M).

Long Term Liabilities: PCRX's short term assets ($658.5M) exceed its long term liabilities ($549.3M).


Debt to Equity History and Analysis

Debt Level: PCRX's debt to equity ratio (78.1%) is considered high.

Reducing Debt: PCRX's debt to equity ratio has increased from 50.1% to 78.1% over the past 5 years.

Debt Coverage: PCRX's debt is not well covered by operating cash flow (12.3%).

Interest Coverage: PCRX's interest payments on its debt are not well covered by EBIT (2.1x coverage).


Balance Sheet


Next Steps

Dividend

What is Pacira BioSciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PCRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PCRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PCRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Dave Stack (70 yo)

13.17yrs

Tenure

US$5,806,428

Compensation

Mr. David M. Stack, also known as Dave, has been the Chief Executive Officer of Pacira Pharmaceuticals Inc. Since 2007, Mr. Stack has served as Chief Executive Officer and Chairman of Pacira BioSciences, I...


CEO Compensation Analysis

Compensation vs Market: Dave's total compensation ($USD5.81M) is about average for companies of similar size in the US market ($USD5.00M).

Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
David Stack
Chairman & CEO13.17yrsUS$5.81m0.27%
$ 8.7m
Charles Reinhart
Chief Financial Officer4.67yrsUS$1.39m0.016%
$ 505.4k
Kristen Williams
Chief Administrative Officer & Secretary6.25yrsUS$1.69m0%
$ 0
Roy Winston
Chief Clinical Officer2.42yrsUS$1.61m0.024%
$ 782.9k
Max Reinhardt
President of ROW0.58yrUS$4.76mno data
Lauren Riker
Principal Accounting Officer & VP of Finance8.83yrsUS$288.82k0.011%
$ 365.2k
Charles Laranjeira
Chief Technical Officer2.08yrsno data0.0013%
$ 40.3k
Susan Mesco
Head of Investor Relationsno datano datano data
Richard Kahr
Vice President of Human Resources5.5yrsno datano data
Robert Weiland
Senior Vice President of Alliance Management4.75yrsUS$1.92mno data
Dennis McLoughlin
Chief Customer Officer2.42yrsUS$2.53m0.014%
$ 443.0k
Ronald Ellis
Senior Vice Presidentno datano datano data

4.7yrs

Average Tenure

54yo

Average Age

Experienced Management: PCRX's management team is considered experienced (4.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Stack
Chairman & CEO13.17yrsUS$5.81m0.27%
$ 8.7m
Laura Brege
Independent Director9.58yrsUS$445.95k0.015%
$ 490.7k
Paul Hastings
Independent Lead Director7.58yrsUS$458.95k0.011%
$ 357.9k
Gary Pace
Independent Director12.58yrsUS$421.95k0.30%
$ 9.5m
Andreas Wicki
Independent Director14.08yrsno datano data
John Longenecker
Independent Director13.5yrsUS$442.95k0.038%
$ 1.2m
Mark Kronenfeld
Independent Director7.58yrsUS$430.95k0.033%
$ 1.1m
Yvonne Greenstreet
Independent Director6.83yrsUS$424.95k0.022%
$ 719.2k
Christopher Christie
Director1.33yrsUS$901.50k0%
$ 0
Mark Froimson
Independent Director3.58yrsUS$424.95k0.011%
$ 347.6k

7.6yrs

Average Tenure

61yo

Average Age

Experienced Board: PCRX's board of directors are considered experienced (7.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.


Top Shareholders

Company Information

Pacira BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pacira BioSciences, Inc.
  • Ticker: PCRX
  • Exchange: NasdaqGS
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.201b
  • Shares outstanding: 43.44m
  • Website: https://www.pacira.com

Number of Employees


Location

  • Pacira BioSciences, Inc.
  • 5 Sylvan Way
  • Suite 300
  • Parsippany
  • New Jersey
  • 7054
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PCRXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2011
82PDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2011

Biography

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 23:14
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.